Correlation of Histological Grade with Hormone Receptors and Her 2 Neu In Carcinoma Breast - A Tertiary Centre Study

Shiv Pankaj Khanna¹, Rigvardhan²

ABSTRACT

Introduction: Hormone receptors and Her 2 Neu status are now widely accepted as a prognostic markers and to decide therapeutic modality in breast carcinoma. The aim of this study was to analyze the receptor status in breast carcinoma with histopathological characteristics of the tumor.

Material and Methods: In the present study, immunohistochemical assay of 60 tumor block of patients of breast carcinoma was performed to know the hormone receptor status as well as histological examination.

Results: 60 breast cancer specimen were available for immunohistochemical testing for ER/PR. The result of the study showed that only 3.33% cases were ER+/PR+, 7.66% cases ER+/PR−, 9.33% ER−/PR+ and 80% cases were ER−/ PR−. Expression of ER and PR was found to be significantly associated with tumor grade.

Conclusion: The Estrogen receptor and Progestrone Receptor negative cases were found in high grade disease on histological evaluation. Their status should be ascertained in all cases of breast carcinomas. Triple negative breast carcinomas have poorer prognosis as they tend to be of high grade.

Keywords: Breast Carcinoma; Estrogen Receptor; Progestrone Receptor; Her 2 Neu

INTRODUCTION

Carcinoma breast is the most frequent cancer among females worldwide. In India, it is the second most common cancer among females after carcinoma cervix. It is leading cause of cancer death in women aged 40 to 44 years, and second leading cause of cancer death for women overall¹. Breast cancer represents about 12% of all new cancer cases and 25% of all cancers in women². Although, incidence of breast cancer is low in India as compared to western countries, it is associated with poor prognosis and high mortality, may be due to late presentation when it in advanced stages¹. Numerous variables such as histological type and grade, tumor size, lymph node status, status of hormonal receptors- estrogen receptor (ER) and Progestrone receptor (PR) of tumor influence the prognosis and management of breast carcinoma³. With advent of adjuvant hormonal or chemotherapeutic regimens determination the ER, PR and human epidermal growth factor receptor-2 (Her2/neu) receptor status in breast cancer has become practice as receptor positive status confer survival advantage in these patients².³. It is well known that strong ER-positive cases benefit from endocrine therapy alone⁴,⁵. PR status is also independently associated with overall and disease free survival. Patients with ER, PR positive tumors have a better prognosis than patients with negative expression⁶. Hormone receptors study is not routinely measured as it is expensive and is still considered a research tool in many parts of our country. This could adversely impact decision making regarding treatment protocol and sometimes patients are treated empirically with tamoxifen which is not always required. The present study was planned keeping in mind predictive importance of receptor status for the prognosis of illness and application of appropriate therapy. The objective was to determine receptor status and it’s correlation with histopathological Grade of the tumor in an Indian population.

MATERIAL AND METHODS

This was a retrospective study carried out in a tertiary care centre in Central India. Samples of Sixty patients with histological proven diagnosis of breast carcinoma from January 2016 to October 2017 were selected for this study. Modified radical mastectomy specimens were subjected to histopathological examination and Immunohistochemical (IHC) analysis. Clinical details were archived from the files. Specimens were routinely fixed 24-48 hours in 10% neutral buffer formalin and were grossly examined and representative tissue bits were taken according to standard guidelines and then processed. 4 micron sections were stained with routine hematoxylin and eosin (H&E) stain. Samples were histologically graded according to Modified Bloom-Richardson-Elston (MRB) grading system. MRB grade was obtained by adding up the scores for tubule formation, nuclear pleomorphism and mitotic count⁷. Each of which was given 1, 2 or 3 points. This resulted in a total score of between 3 and 9. The final grading was given as below

1. 3 to 5 points – grade I
2. 6 to 7 points– grade II
3. 8 to 9 points– grade III.

ER / PR and Her-2Neu status was evaluated by IHC technique with monoclonal antibodies (DAKO) using

¹Associate Professor, Department of Pathology, Command Hospital, Lucknow; ²Associate Professor, Department of Pathology, Saraswati Medical College, Unnao

Corresponding author: Dr Rigvardhan, Associate Professor, Department of Pathology, Saraswati Medical College, Unnao – 209859; India

How to cite this article: Shiv Pankaj Khanna, Rigvardhan. Correlation of histological grade with hormone receptors and Her 2 Neu in carcinoma breast - a tertiary centre study. International Journal of Contemporary Medical Research 2018;5(5):E6-E8.

DOI: http://dx.doi.org/10.21276/ijcmr.2018.5.5.33
antigen-antibody Streptavidin immunoperoxidase method. Positive and negative controls were simultaneously run with each batch of IHC staining. Tumors that showed strong complete membranous staining in > 10% cells were taken as positive for Her-2neu. Nuclear staining was taken as positive for estrogen and progestrone receptors. ER/PR expressions were assessed by Quick scoring which is based on assessment of proportion score and intensity score. The 2 scores are added together for a final score with 8 possible values. A simplified Allred score groups 0 and 2; 3 and 4; 5 and 6; and 7 and 8 for 4 possible values (Tables 1 and 2).

**RESULTS**

Sixty cases of breast carcinomas cases were ascertained for ER/PR status in relation to histological grading of tumor. In the present study female patients with breast carcinoma were aged between 24-79 years with youngest being 24 years and oldest 79 years. The mean age was 54.1 years. Majority (63%) were in age group of 40 to 59 yrs. The morphological categories were infiltrating ductal carcinoma, not otherwise specified (51 cases- 85%) followed by medullary carcinoma (6 cases, 10%); infiltrating lobular carcinoma, mucinous carcinoma and infiltrating papillary carcinoma 1 (1.66%) case each.

The most frequent tumor grade was grade II (53.33%) followed by grade III (36.66%) and grade I (10%) (Table 3). The result of the study showed that only 3.33% cases were ER+/PR+, 7.66% cases ER+/PR-, 9.33% ER-/PR+ and 80% cases were ER-/PR-. Expression of ER and PR found to be significantly associated with tumor grade (p=0.02) (Tables 3-6). Her 2 Neu status was as per table 7.

**DISCUSSION**

ER, PR and her2/neu are well-established procedures in routine breast cancer management mainly as prognostic factors for adjuvant hormone therapy. In our study, we found expression of ER to be only 20% and PR only 23.33%. Hormonal receptor status has shown that overall positivity rate for ER and PR is lower in India as compared to Western literature. In European and American population, 60-80% patients were found with positive receptor expression. This may be due to lower average age at diagnosis or racial difference. The tumor grade II were more common in our study followed by grade III and I contrast to other studies. Increased histological grade and late presentation possibly reflects lack of health awareness and miscellaneous social taboos in this part of the country. In our study, ER and PR correlated well with grade I (p=0.001 and p=0.02 respectively). Tumor grade is one of the important predictors of tumor behavior in breast cancer. Our results confirmed that non-reactivity of hormonal receptors increases with increase in tumor grade. Infiltrating ductal carcinoma was the most common histological type similar to other studies followed by medullary carcinoma in our study where as in other studies infiltrating lobular carcinoma being the second most common type.

Triple-negative breast cancer (TNBC) is defined as a that group of breast carcinomas that are negative for ER, PR and HER2 status...
HER2/neu. In our study, of 60 cases, we found 8 such tumors. All 8 cases were infiltrating ductal type of carcinomas. All of them were of grade II or III. 75% had lymph node metastasis and lymphatic vessel invasion and 62.5% had tumor necrosis. Our results showed that TNBC had poor prognostic characteristics as compared with other subtypes of breast cancers. Other authors have also found similar results. Although patients with TNBC tend to have a poor prognosis, only chemotherapy is expected to be effective because no therapeutic targets have yet been established. Our study also reveals for a non-significant association between expression of ER/PR and lymph node metastasis. Similar results have been documented in other studies.

CONCLUSION

Immunohistochemical analysis of ER, PR and Her2 Neu is widely accepted to have prognostic implications and are vital in deciding treatment modality. This study confirms that receptor expression of ER and PR is significantly associated with tumor grade. However, No association with node metastasis and ER, PR expressions was observed. High percentage of grade II and III tumours in our centre highlights the need to increase health awareness in this area in order to decrease the morbidity and mortality. Further functional analysis of ER, PR and Her 2Neu receptors are needed to investigate the effects of compounds in inhibiting cancer in humans. These findings can have profound impact in breast cancer treatment.

REFERENCES

1. Kumar N, Mukherjee S. Correlation of various prognostic factors in breast cancer. International Journal of Scientific and Research Publications 2013; 3:1-4.
2. Amit M, C Prasad, Sreeramu P, Srinivasan D, Naveedahmed k, Ruta U J. Histopathological Grade versus Estrogen and Progestrogn Receptor Status in Carcinoma Breast- A Single Center Study. Open Access J Surg. 2017; 4: 555639.
3. Roy I, Othieno E. Breast carcinoma in Uganda: Microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med 2011;135: 194-199.
4. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
5. Gupta D, Gupta V, Marwah N, Gill M, Gupta S, Gupta G et al. Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors. Iranian Journal of Pathology 2015;10:23 – 34.
6. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and HER2/neu expression: Comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
7. Silverberg SG, DeLellis RA, Frable WJ, Livolsi VA, Wick MR. Silverberg’s Principles and Practice of Surgical Cytopathology. 4th ed. Philadelphia: Churchill Livingstone; 2006.
8. Bancroft JD, Gamble M. Theory and Practice of Histologic techniques. 6th ed. Philadelphia: Churchill Livingstone; 2008.
9. Rosai J. Rosai and Ackerman’s Surgical Pathology. 9th ed. Missouri: Mosby; 2004
10. Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a pratically useful evaluation system and handling protocol. Breast Cancer 2006; 13: 232-235.
11. Bast RC, Ravdin P, Hayes DF, Bates S, Fritzche H, et al. 2000 update of recommendations for use of tumor markers in breast and colorectal cancer: clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 2001;19: 1865-1878.
12. Donegan WL. Tumor-related prognostic factors for breast cancer. Cancer J Clin 1997;47: 28-51.
13. Mudduwa LK. Quick score of hormone receptor status of breast carcinoma: Correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol 2009;52:159-163.
14. Kaul R, Sharma J, Minhas SS, Mardik K. Hormone receptor status of breast cancer in the himalayan region of northern India. Indian J Surg 2011;73: 9-12.
15. Suvarchala SB, Nageswararao R. Carcinoma breast histopathological and hormone receptors correlation. J Biosci Technol 2011; 2: 340-348.
16. Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in the United States. J clin Oncol 2005;23: 7836-7841.
17. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 2010;17:118-24.
18. Ariga R, Zarf I, Korasick J, Reddy V, Siziopicou K, et al. Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11: 278-280.

Source of Support: Nil; Conflict of Interest: None

Submitted: 06-05-2018; Accepted: 09-06-2018; Published: 17-06-2018